Adherence to the Mediterranean Diet and Risk of Metabolically Unhealthy Obesity in Women: A Cross-Sectional Study

Alessandro Leone1,*, Ramona De Amicis1, Alberto Battezzati1 and Simona Bertoli1,2

1 International Center for the Assessment of Nutritional Status, Department of Food, Environmental and Nutritional Sciences, University of Milan, Milan, Italy, 2 Lab of Nutrition and Obesity Research, Istituto Auxologico Italiano, IRCCS, Milan, Italy

Some obese individuals do not present any metabolic alteration and are considered metabolically healthy (MHO). Adherence to high-quality dietary pattern may favor this phenotype. We aimed to evaluate the association between the adherence to the Mediterranean diet and risk of metabolically unhealthy obesity (MUO) in women. We conducted a cross-sectional study on 2,115 obese women. All patients underwent a medical examination, anthropometric evaluation, bioelectrical impedance, ultrasound measurements of abdominal visceral (VAT) and subcutaneous (SAT) fat, blood sampling and evaluation of adherence to the Mediterranean diet through MEDAS questionnaire. The diagnosis of MHO and MUO was made using the harmonized criteria. A multivariable logistic regression adjusted for age, BMI, fat free mass, ultrasound-estimated VAT:SAT ratio, marital status, education, past diet, antidepressant use, family history of diabetes and cardiovascular disease, menopausal status, smoking, and physical activity was used to assess the association between Mediterranean diet and MUO risk. The prevalence of MHO was 21.2% (N = 449). Compared to MUO women, MHO women were younger, had lower BMI and VAT, and had higher fat free mass and SAT. In the multivariable model, the adherence to the Mediterranean diet was not associated with the risk of MUO (OR = 0.91, 95%CI: 0.62; 1.34, P = 0.624). Given the impact of menopause on metabolic health we also carried out the analysis in pre- and post-menopausal women separately. Higher adherence to the Mediterranean diet was associated with a lower risk of MUO in postmenopausal women (OR = 0.55, 95%CI: 0.31; 0.96, P = 0.034). No association was found in premenopausal women (OR = 1.18, 95%CI: 0.70; 1.99, P = 0.532). In conclusion, adherence to the Mediterranean diet was associated with a better metabolic health in postmenopausal women. Further studies are needed to confirm the ability of the Mediterranean diet in promoting maintenance of the healthy phenotype and reversion from MUO.

Keywords: metabolically healthy obesity, obesity phenotypes, mediterranean diet, metabolic syndrome, women
INTRODUCTION

Obesity is a complex, multifactorial disease that affects 13% of the population worldwide (1). It represents a major public health problem, with a significant impact on health and national health expenditure (2). Obese people have an increased risk for many metabolic complications and chronic diseases, such as type 2 diabetes, cardiovascular disease, and some forms of cancer, as well as a reduction in life expectancy (3, 4). Moreover, recent evidence has led to the conclusion that obesity is a risk factor for the communicable disease COVID-19 (5) and might also promote vaccine-breakthrough SARS-CoV-2 infections in fully vaccinated people (6). Despite this, some obese individuals do not present metabolic abnormalities and are therefore considered metabolically healthy (MHO) (7). A meta-analysis of 12 cohort studies and 7 intervention studies found that 35% of obese people were metabolically healthy, with significant differences among countries (8). In Italy, the prevalence of MHO ranged from 11.5 to 29.2%, with higher rates in women (9). Several studies have shown that MHO individuals have a lower risk of developing type 2 diabetes, cardiovascular disease and premature death than individuals with a metabolically unhealthy phenotype (MUO) (10–12). Adipose tissue plays a central role in defining the metabolic phenotype of obesity (13). The expandability of subcutaneous adipose tissue, particularly in the gluteofemoral region is considered beneficial for metabolic health and preservation of insulin sensitivity. On the other hand, MUO individuals are characterized by adipocyte hypertrophy, increased visceral and subcutaneous abdominal adipose tissue, and increased ectopic lipid deposition in organs such as liver and skeletal muscle (14). This hypertrophic adipose tissue is also characterized by increased macrophage infiltration, inflammation, and altered adipokines secretion. Together, these disturbances may lead to the development of peripheral insulin resistance (15). However, it must be said that metabolic health is a transient state for a large proportion of women with obesity (16). With aging, in fact, there is a decline in the capacity of subcutaneous adipose tissue to respond to overfeeding by hyperplasia and a redistribution of adipose tissue. In women, the turning point is represented by menopause, and are therefore considered metabolically healthy (MHO) (7). However, evidence on this topic is still limited, and therefore, to test our hypothesis, we assessed the adherence to the Mediterranean diet in a sample of obese women who were then classified as MHO and MUO.

MATERIALS AND METHODS

Study Design

We conducted a cross-sectional study on patients recruited at the International Center for the Assessment of Nutritional Status (ICANS), a nutritional outpatient clinic of the University of Milan that started its clinical activity in 2003. The promotion of the clinical activity took place, initially, through the use of flyers and newspaper advertisement, and then through a web page. Patients came to ICANS on a voluntary basis or sent by their general practitioner or a specialist. The objective was to perform a nutritional assessment aimed at obtaining a personalized dietary program for weight loss and/or improvement of metabolic parameters, or to perform specific instrumental and/or laboratory evaluations. The data collected were entered into an electronic medical record and, after obtaining a signed informed consent, conveyed into a large database and used, in an anonymized manner, for research purposes.

For the study, we selected obese women (BMI ≥ 30 kg/m²), aged ≥ 18 years, not previously diagnosed with type 1 and 2 diabetes and cardiovascular disease, not having neurological, gastrointestinal, cardiac, renal, and pulmonary failure, cancer in the last 5 years, and acute illness, not using drugs known to cause lipodystrophy including steroids and antiretroviral agents, and come to ICANS before the COVID-19 pandemic. Up to February 2020, 2,757 obese women with the characteristics described above had been recruited. To be eligible for the study, all women should have been subjected to a medical examination, anthropometric evaluation, bioelectrical impedance, ultrasound measurements of abdominal fat, blood sampling and evaluation of adherence to the Mediterranean diet through a dietary screener. Therefore, we excluded 507 women who had performed only specific instrumental and/or laboratory evaluations, and 135 women who did not complete (≥ 1 item missing) the dietary screener for the assessment of the adherence to the Mediterranean diet. The characteristics of excluded women are given in Supplementary Table 1. Women included in the study were significantly younger, especially compared with women excluded because they had one or more missing items in the MEDAS questionnaire. The latter had less fat free mass (FFM) and greater abdominal visceral fat (VAT) thickness, as well as being less educated.
The study was conducted following the guidelines laid down in the Declaration of Helsinki and the Ethics Committee of the University of Milan gave a positive opinion on study procedures (protocol no. 23/2016).

**Measurements**

On arrival at ICANS, the patients completed a short questionnaire investigating socio-demographic information. Between 08:30 and 09:00 AM, a physician took a blood sample from the fasting patient. The sample was then centrifuged and an aliquot of serum was used for the determination of blood glucose, triglycerides and HDL-cholesterol. The above biochemical parameters were measured by enzymatic method (Cobas Integra 400 Plus, Roche Diagnostics, Rotkreuz, Switzerland). The physician then conducted a medical examination to obtain information about any past dietary interventions, patient’s medical history, family history of diabetes and cardiovascular disease, lifestyle, with particular regard to smoking and weekly structured physical activity, and menopausal status. Menopause has been defined as the absence of a menstrual cycle for at least 12 months. The physician performed an ultrasound measurement of abdominal visceral and subcutaneous (SAT) fat using a Logiq 3 Pro instrument equipped with a 7.5 MHz linear probe and with a 3.5 MHz convex-array probe (GE Healthcare, Chicago, IL, United States). The measurements were taken 1 cm above the umbilicus at the end of expiration. SAT, measured with the 7.5 MHz linear probe, was defined as the distance between the epidermis and the external face of the rectus abdominis muscle; VAT, measured with the 3.5 MHz convex-array probe, was defined as the distance between the anterior wall of the aorta and the posterior surface of the rectus abdominis muscle (29, 30). The physician then performed systolic and diastolic blood pressure measurements in accordance with JNC-7 guidelines (31).

A registered dietician took the anthropometric measurements according to international guidelines (32) and performed body composition assessment by bioelectric impedance. Weight was taken with an electronic scale and rounded to the nearest 100 g (Seca 700 balance, Seca Corporation). Height was measured with a vertical stadiometer with an accuracy of 0.1 cm. Body mass index (BMI) was then calculated and classified using WHO cut-offs (33). Waist circumference (WC) was measured with a non-elastic tape at the midpoint between the last rib and the iliac crest with an accuracy of 0.5 cm. Body composition was assessed using a tetra polar 8-point tactile electrode system (InBody 720, Biospace, Seoul, South Korea) at 1, 5, 50, 250, 500, and 1,000 kHz. Participants stood on the scale platform of the instrument and grasped the handles of the device, to provide contact with a total of eight electrodes (two for each foot and for each hand). Manufacturer’s equations were used to estimate total body fat and FFM. All measurements were taken with the patient wearing only light clothes.

**Outcome Assessment**

The diagnosis of MHO and MUO was made using the harmonized criteria proposed by Lavie et al. (34) (Table 1). Briefly, a women was classified as MHO if she met no criteria for metabolic syndrome (MetS), with the exclusion of high WC.

---

### Table 1 | Diagnostic criteria for metabolic phenotypes of obesity.

| Definition of MHO | Definition of MUO |
|-------------------|-------------------|
| A women has been classified as MHO if met 0 of the 4 MetS criteria (WC excluded), which are the following: | A women has been classified as MUO if met 1 to 4 of the MetS criteria reported above (WC excluded). |
| • Elevated triglycerides or drug treatment for elevated triglycerides | ≥ 150 mg/dl (1.7 mmol/l) |
| • Reduced high-density lipoprotein cholesterol or drug treatment for reduced HDL | <50 mg/dl (1.3 mmol/l) |
| • Elevated blood pressure or antihypertensive drug treatment | Systolic blood pressure ≥ 130 mm Hg and/or diastolic blood pressure ≥ 85 mm Hg |
| • Elevated fasting glucose or drug treatment of elevated glucose | ≥ 100 mg/dl (5.6 mmol/l) |

Conversely, a women was classified as MUO if she met 1 to 4 MetS criteria (WC excluded).

**Exposure Assessment**

During the morning, patients completed the MEDiterranean Diet Adherence Screener (MEDAS) (35), a 14-item questionnaire developed in the PREDIMED trial. The questionnaire investigates some dietary habits, the consumption of typical foods of the Mediterranean diet (oil, vegetables, fruit, wine, legumes, fish, nuts, white meat, and use of soffritto) and the consumption of unhealthy foods (red and processed meat, animal fat, sugary and carbonated beverages and sweets). For each item a 1 point is given if the consumption meets the criteria of adherence to the Mediterranean diet (Table 2). The sum of the individual points gives a Mediterranean score, which is a number between 0 and 14. A score ≥ 9 is considered an indication of adherence to the Mediterranean diet (36–38).

**Statistical Analysis**

Continuous variables are reported as median and interquartile range (IQR), as many of them did not follow a normal distribution. Discrete variables are reported as frequency and percentage. Mann-Whitney test and Chi-squared test were used to compare distributions and proportions, respectively. A logistic regression model was fitted to assess the association between adherence to the Mediterranean diet and metabolic phenotype of obesity. Odd ratios (OR) and respective confidence intervals (CI) were calculated including the metabolic phenotype of obesity as a dependent variable (0 = MHO and 1 = MUO), and adherence to the Mediterranean diet as an independent variable (0 = non-adherent and 1 = adherent). To control for potential confounders, we used a pre-specified multivariate model, selecting variables on the basis of biological plausibility. Results were adjusted for age (continuous), BMI (continuous), FFM (continuous), ultrasound-estimated VAT:SAT ratio (continuous),
TABLE 2 | Questions and criteria for assessing the adherence to the Mediterranean diet.

| MEDAS question                      | Criteria for 1 point                  |
|-------------------------------------|---------------------------------------|
| 1. Do you use olive oil as the principal source of fat for cooking? | Yes                                   |
| 2. How much olive oil do you consume per day (including that used in frying, salads, meals eaten away from home, etc.)? | ≥4 table spoons/day                   |
| 3. How many servings of vegetables do you consume per day? | ≥2 servings/day                       |
| 4. How many pieces of fruit (including fresh-squeezed juice) do you consume per day? | ≥3 servings/day                       |
| 5. How many servings of red meat, hamburger, or sausages do you consume per day? | <1 serving/day                        |
| 6. How many servings of butter, margarine, or cream do you consume per day? | <1 serving/day                        |
| 7. How many carbonated or sugar-sweetened beverages do you consume per day? | <1 serving/day                        |
| 8. Do you drink wine? How much do you consume per week? | ≥3 glasses/week                       |
| 9. How many servings of pulses do you consume per week? | ≥3 servings/week                      |
| 10. How many servings of fish/seafood do you consume per week? | ≥3 servings/week                      |
| 11. How many times do you consume commercial (not homemade) pastry such as cookies or cake per week? | <3 times/week                        |
| 12. How many times do you consume nuts per week? | ≥1 servings/week                      |
| 13. Do you prefer to eat chicken, turkey, or rabbit instead of beef, pork, hamburgers, or sausages? | Yes                                  |
| 14. How many times per week do you consume dishes prepared softtito? | ≥2 servings/week                      |

marital status (unmarried, married, widower/separated), education (elementary or middle school, high school, master degree or higher), past diet (yes, no), antidepressant use (yes, no), family history of diabetes (yes, no) and cardiovascular disease (yes, no), menopausal status (premenopausal, postmenopausal), smoking (never, former, current), and physical activity (no, at least 2 h/week). No evidence of multicollinearity was found. The linearity of continuous variables was tested using multivariable fractional polynomials. Following this approach, we found that using untransformed variables ensured better fits for the model. We assessed the goodness of fit (GOF) of the models using the standardized Pearson test. In view of the available knowledge, we consider this to be a sufficient proof of the acceptable fit of the model (39). A $p$-value of $<0.05$ was considered statistically significant. Statistical analysis was performed using STATA version 12.0 (StataCorp, College Station, TX, United States).

RESULTS

We included 2,115 obese women with a median age of 49 years (IQR: 40; 58 years) and a median BMI of 33.3 kg/m$^2$ (IQR: 31.4; 36.3 kg/m$^2$). Fifteen percent of the women had previously followed a dietary program aimed at weight loss, and 36% reported to be engaged in structured physical activity for at least 2 h/week. Women who followed a diet in the past were more physically active (69%) than women who never followed a diet program to lose weight (31%, $p < 0.001$). Supplementary Table 2 gives an overview of the food consumption of recruited women.

Table 3 shows the characteristics of the patients recruited for the study according to metabolic phenotype. In our sample, 449 (21.2%) women were free of metabolic abnormality and were classified as MHO, while the remaining 78.8% of women had at least one metabolic alteration and were classified as MUO. Compared to MUO women, MHO women were younger. Prevalence of MHO decreased with each decade (38.0% at 18–29 years, 37.8% at 30–39 years, 25.6% at 40–49 years, 13.2% at 50–59 years, 7.2% at 60–69 years and 3.4% at ≥70 years; $P < 0.001$). MHO women had lower BMI and ultrasound-estimated VAT and a higher FFM and ultrasound-estimated SAT than MUO women. No difference between the two groups was observed regarding adherence to the Mediterranean diet. Overall, adherence to the Mediterranean diet was found in 264 women (11.6%). As expected, adherence to the Mediterranean diet was influenced by age (6.7% at 18–29 years, 7.8% at 30–39 years, 7.3% at 40–49 years, 11.8% at 50–59 years, 21.6% at 60–69 years and 17.8% at ≥70 years; $P < 0.001$).

When we studied the association between adherence to the Mediterranean diet and the risk of MUO (Table 4), we found no association in the multivariable model (OR = 0.91, 95%CI: 0.62; 1.34, $P = 0.624$). Given the impact of menopause on metabolic health we also carried out the analysis in pre- and post-menopausal women separately. We found that following a Mediterranean diet was associated with a lower risk of MUO in postmenopausal women (OR = 0.55, 95%CI: 0.31; 0.96, $P = 0.034$). No association was found between adherence to the Mediterranean diet and risk of MUO in premenopausal women (OR = 1.18, 95%CI: 0.70; 1.99, $P = 0.532$). Table 5 show the adjusted ORs in sensitivity analysis after modifying some our assumptions. The results did not change when we included women with one or more missing items in the MEDAS questionnaire and after exclusion of women who followed a structured dietary program aimed at weight loss in the past, taking antidepressants and declared cured of cancer for at least 5 years. When we included women with missing information on body composition (ultrasound-estimated VAT and SAT and/or FFM) the statistical significance was marginally lost ($P = 0.068$) in postmenopausal women. Note, however, that to conduct the latter analysis, we had to remove the variables of body composition and abdominal fat distribution from the confounders.

DISCUSSION

In this study, the adherence to the Mediterranean diet was favorably associated with metabolic phenotype of obesity in older women. More specifically, the adherence to the Mediterranean diet was associated with a lower likelihood of MUO in postmenopausal women, independent of wide range on known confounders. Moreover, the result appears...
TABLE 3 | Characteristics of patients.

| Characteristics                        | MHO N = 449 | MUO N = 1666 |
|----------------------------------------|-------------|--------------|
| **Age (years)**                        | Median 41 IQR 34; 49 | Median 51 IQR 42; 60 | <0.001 |
| **BMI (kg/m^2)**                       | Median 32.3 IQR 31.0; 34.1 | Median 33.7 IQR 31.6; 36.8 | <0.001 |
| **Fat Free Mass (%)**                  | Median 59.3 IQR 57.5; 61.0 | Median 57.3 IQR 55.3; 59.1 | <0.001 |
| **Waist circumference (cm)**           | Median 100.5 IQR 96.0; 105.7 | Median 105.6 IQR 100.2; 112.0 | <0.001 |
| **Visceral fat (mm)**                  | Median 45.3 IQR 35.0; 58.2 | Median 63.7 IQR 48.5; 80.6 | <0.001 |
| **Subcutaneous fat (mm)**              | Median 36.4 IQR 29.1; 43.5 | Median 33.9 IQR 26.9; 42.1 | <0.001 |
| **VAT:SAT ratio**                      | Median 1.2 IQR 0.9; 1.8 | Median 1.8 IQR 1.8 | <0.001 |
| **Triglycerides (mg/dl)**              | Median 75 IQR 59; 97 | Median 108 IQR 80; 148 | <0.001 |
| **HDL cholesterol (mg/dl)**            | Median 63 IQR 59; 71 | Median 56 IQR 48; 66 | <0.001 |
| **Serum glucose (mg/dl)**              | Median 90 IQR 86; 94 | Median 98 IQR 91; 105 | <0.001 |
| **Systolic blood pressure (mm Hg)**    | Median 120 IQR 110; 120 | Median 130 IQR 120; 140 | <0.001 |
| **Diastolic blood pressure (mm Hg)**   | Median 75 IQR 70; 80 | Median 80 IQR 80; 85 | <0.001 |
| **Mediterranean score**                | Median 6 IQR 5; 7 | Median 7 IQR 5; 8 | 0.009 |
| **Marital status**                     |             |              |
| Not married                            | 194 43.2 %   | 510 30.6 %   | <0.001 |
| Married                                | 215 47.9 %   | 961 57.7 %   |          |
| Divorced or widower                    | 40 8.9 %     | 195 11.7 %   |          |
| **Education**                          |             |              |
| Elementary or middle school            | 56 12.5 %    | 255 15.3 %   | 0.262 |
| High school                            | 239 53.2 %   | 883 53 %     |          |
| Master degree or higher               | 154 34.3 %   | 528 31.7 %   |          |
| **Smoking**                            |             |              |
| Not smoker                             | 261 58.1 %   | 925 55.5 %   | 0.613 |
| Ex-smoker                              | 86 19.2 %    | 341 20.5 %   |          |
| Smoker                                 | 102 22.7 %   | 400 24 %     |          |
| **Structured physical activity**       |             |              |
| No                                     | 286 63.7 %   | 1056 63.4 %  | 0.903 |
| At least 2 h/week                      | 163 36.3 %   | 610 36.6 %   |          |
| **Menopausal status**                  |             |              |
| Premenopausal                          | 347 77.3 %   | 740 44.4 %   | <0.001 |
| Postmenopausal                         | 102 22.7 %   | 926 55.6 %   |          |
| **Familiarity for diabetes**           |             |              |
| No                                     | 291 64.8 %   | 1047 62.8 %  | 0.443 |
| Yes                                    | 158 35.2 %   | 619 37.2 %   |          |
| **Familiarity for CVD**                |             |              |
| No                                     | 299 66.6 %   | 1143 68.6 %  | 0.416 |
| Yes                                    | 150 33.4 %   | 523 31.4 %   |          |
| **Cancer**                             |             |              |
| Healed for at least 5 years            | 23 5.1 %     | 116 7.0 %    | 0.163 |
| Never been diagnosed                   | 426 94.9 %   | 1550 93.0 %  |          |
| **Past dietary program**               |             |              |
| No                                     | 386 86 %     | 1407 84.5 %  | 0.428 |
| Yes                                    | 63 14 %      | 259 15.5 %   |          |
| **Using antidepressants**              |             |              |
| No                                     | 426 94.9 %   | 1565 93.9 %  | 0.452 |
| Yes                                    | 23 5.1 %     | 101 6.1 %    |          |

TABLE 3 (Continued)

| Characteristics                        | MHO N = 449 | MUO N = 1666 |
|----------------------------------------|-------------|--------------|
| **Treatment for high triglycerides**   |             |              |
| No                                     | 449 100 %   | 1525 91.5 %  | <0.001 |
| Yes                                    | 0 0 %       | 141 8.5 %    |          |
| **Treatment for low HDL cholesterol**  |             |              |
| No                                     | 449 100 %   | 1664 99.9 %  | 0.463 |
| Yes                                    | 0 0 %       | 2 0.1 %      |          |
| **Treatment for high blood pressure**  |             |              |
| No                                     | 449 100 %   | 1226 73.6 %  | <0.001 |
| Yes                                    | 0 0 %       | 440 26.4 %   |          |
| **Adherence to the Mediterranean diet**|             |              |
| Not adherent                           | 404 90.0 %  | 1470 88.2 %  | 0.302 |
| Adherent                               | 45 10.0 %   | 196 11.8 %   |          |

TABLE 4 | Association between the adherence to the Mediterranean diet risk of metabolically unhealthy obesity.

| Adherence to the Mediterranean diet | Not adherent | Adherent | P-value |
|------------------------------------|--------------|----------|---------|
| Overall                            | MHO/MUO      | 404/1470 | 45/196  |
| Median score                       | 6            | 9        |         |
| OR (95%CI)                         | 0.91 (0.62; 1.34) | 0.624 |
| Premenopausal women                | MHO/MUO      | 321/683  | 26/57   |
| Median score                       | 6            | 9        |         |
| OR (95%CI)                         | 1.18 (0.70; 1.99) | 0.532 |
| Postmenopausal women               | MHO/MUO      | 83/787   | 19/139  |
| Median score                       | 7            | 9        |         |
| OR (95%CI)                         | 0.55 (0.31; 0.96) | 0.034 |

Models adjusted for age, BMI, fat free mass (%), VAT:SAT ratio, past diet, marital status, education, smoking, physical activity, menopausal status, familiarity for diabetes and cardiovascular disease and antidepressants use.

robust, such that sensitivity analysis did not show major losses of statistical significance regarding the association between adherence to the Mediterranean diet and metabolic health in postmenopausal women. Only when we included women with missing information on body composition and abdominal fat distribution, the association was marginally lost. However, in the latter case we had to remove these important confounders from the analysis, and this may explain the marginal loss of significance.

Metabolically healthy obesity is a phenotype of obesity characterized by the absence of metabolic alterations. In agreement with previous epidemiological studies, approximately
one in five obese women in our sample had this metabolic phenotype (9, 13), but the prevalence was influenced by age. Our results confirm the differences in body composition and adipose tissue distribution between the two metabolic phenotypes of obesity (15). Women with the healthy phenotype had higher FFM and ultrasound-estimated SAT, whereas women with the unhealthy phenotype had greater amount of fat mass and ultrasound-estimated VAT. Previous epidemiological studies report similar caloric and nutrient intakes, as well as equal consumption of different food groups, among MHO and MUO individuals (40–42). However, studying the dietary pattern may better inform the holistic effect of diet on healthy obesity (42). Assessment of dietary patterns avoids potential confounding with other aspects of the diet, increases the ability to assess stronger effects due to the cumulative effects of many dietary characteristics, and allows assessment of the interaction between synergistic components (43–46). Indeed, current evidence, although still limited, suggests that adherence to high-quality dietary patterns, may positively affect the metabolic phenotype of obesity (47). Our results confirm this evidence, suggesting (1) that adherence to the Mediterranean diet is associated with a lower risk of MUO, (2) that the effect of dietary pattern might be greater, with regard to obese women, in postmenopausal women, and (3) that the contribution of the Mediterranean diet to metabolic health is independent of body composition and abdominal fat distribution. In a previous study where a group of pre- and post-menopausal women underwent dietary intervention to lose weight, both groups had significant body weight loss, but only the postmenopausal women had an improvement in MetS parameters (48). In younger women, the protective action of estrogen may reduce the contribution of diet to metabolic health. Estrogen drives fat accumulation in gluteofemoral adipose tissue rather than visceral adipose tissue (49, 50), and gluteofemoral adipose tissue is thought to be protective against the negative effects of obesity (51). Estrogens also have anti-inflammatory and antioxidant properties, as they reduce the release of pro-inflammatory cytokines by immune cells, and increased resistance to oxidative stress (50, 52). Consistent with these findings, when compared with postmenopausal women, premenopausal women have been found less insulin resistance (52). The protective effect is lost with the withdrawal of estrogen after menopause. As a consequence, fat accumulation in visceral adipose tissue increases, as does the risk of developing insulin resistance and CVD (52). It is therefore possible that when estrogen protection is lost, diet becomes more relevant. An alternative explanation could be related to the low adherence to the Mediterranean diet observed in younger women. This finding confirms the abundant evidence showing that younger segments of the population are abandoning the Mediterranean dietary pattern in favor of the less healthy, but more appealing, Western dietary patterns (38, 53).

Our results find consistency in a cohort study conducted within the PREDIMED trial, where greater adherence to the Mediterranean diet, assessed through the MEDAS screening tool, was associated with transition to the healthy obesity phenotype in men and women aged 55 years and older (54). In contrast, they differed from the results of a previous cross-sectional study, where a higher Mediterranean diet score was associated with a higher likelihood of MHO in men aged <45 years and premenopausal women, but not in the older age groups (55).
discrepancy could lie in the different assessment tool for dietary habits, in the intrinsic differences in the studied populations (American population vs. Mediterranean population), as well as in the different definition of MHO. The lack of universally recognized criteria to define MHO makes it difficult to compare studies. The criteria proposed by Lavie et al. (34) and that we used in the present study are based on the harmonized criteria for the diagnosis of MetS (56), parameters that are readily available and widely used in routine clinical practice and research, making our findings, in fact, more easily comparable. Moreover, they define the MHO phenotype as free of metabolic alterations. The presence of even a single metabolic alteration is instead to be considered at risk of cardiovascular event, as the latter increases progressively with the number of metabolic alterations (57).

Several beneficial effects attributable to the Mediterranean diet could explain its role in promoting metabolic health. It has been reported from both prospective cohort studies and intervention trials how the Mediterranean diet, even in the absence of energy restriction, prevent weight gain (19, 21–23). In addition, several evidences suggest that adherence to the Mediterranean diet reduces liver fat content (58, 59), and, thereby, improves glucose and lipid metabolism, and, also via regulation of hepatokine release, impacts on the cardiomtabolic risk (60). Finally, several bioactive compounds introduced by following a Mediterranean diet, such as polyphenols, mono and polyunsaturated fatty acids, micronutrients and antioxidants, contribute to metabolic health by reducing oxidative stress and inflammation (61, 62). On the other hand, it is presumable that women with lower adherence to the Mediterranean diet followed a diet that was higher in high-calorie foods of low nutritional quality. This may have contributed to a higher intake of refined carbohydrates and sugars, saturated fat, salt and additives, and a lower intake of fiber and micronutrients, promoting visceral fat accumulation (54) and a low-grade inflammatory state (63, 64), risk factors for developing insulin-resistance (65).

Several strengths characterize the present study. First, the large sample size. Second, we were able to control for a wide range of confounders, including body weight and composition, estimates of visceral and subcutaneous abdominal fat, education and marital status, assumed to be proxies for socioeconomic status and access to health care, family history of diabetes and cardiovascular disease, menopausal status and lifestyle. All variables known to influence metabolic status.

We are well aware, however, that the study is not without limitations. First, the cross-sectional design does not allow for a cause-effect relationship. Second, we included only women. Third, we used a short dietary screener to assess adherence to the Mediterranean diet, so a limited number of foods were considered. However, the questionnaire was shown to have a good agreement with Mediterranean diet adherence estimated by a FFQ (35). Fourth, the use of a self-completed dietary questionnaire may have been difficult for older, less educated women to understand, causing selection bias. However, exclusion of these women did not appear to affect the association between Mediterranean diet and metabolic health. Fifth, the use of non-gold standard techniques for the assessment of body composition and abdominal adipose tissue distribution calls for caution in the interpretation of results. To this should be added that no comparison with reference methods was made in this study. In fact, we used bioelectrical impedance, which, although widely used in clinical settings, provides an estimate of the amount of FFM. We also performed an estimation of visceral and subcutaneous abdominal adipose tissue by ultrasonography, which, although some published works show good correlation between ultrasound thicknesses of VAT and SAT and the respective areas measured by computed tomography and MRI (29, 66), is not the reference technique for the evaluation of abdominal adipose tissue distribution. Sixth, our study included only Caucasian women, and, therefore, these findings cannot be transferred to women of other ethnicities without a prior confirmation. Seventh, the use of hormone replacement therapy in the years after menopause may have influenced the risk of metabolic alterations. Finally, as in any observational study, potential residual confounding could not be ruled out.

CONCLUSION

In conclusion, adherence to the Mediterranean diet in obese women is associated with a better metabolic health. The contribution of diet seems to be more relevant in postmenopausal. Further prospective epidemiological studies and clinical trials are needed to confirm that the Mediterranean diet may promote maintenance of the healthy metabolic phenotype and reversion from the unhealthy phenotype.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article is available from the corresponding author on reasonable request.

ETHICS STATEMENT

The study procedures were reviewed and approved by the Ethics Committee of the University of Milan. Patients provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

AL: conceptualization, data curation, formal analysis, investigation, supervision, visualization, methodology, writing – original draft, and writing – review and editing. RD: investigation and writing – review and editing. AB: investigation, funding acquisition, and writing – review and editing. SB: conceptualization, investigation, funding acquisition, and writing – review and editing. All authors contributed to the article and approved the submitted version.
ACKNOWLEDGMENTS

We wish to thank the International Center for the Assessment of Nutritional Status research staff and especially Laila Vignati, The University of Milan partially covered the open access APC through the APC initiative.

REFERENCES

1. World Health Organization [WHO]. Obesity and Overweight. Geneva: World Health Organization (2021).
2. Okunogbe A, Nugent R, Spencer G, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for eight countries. BMJ Global Health. (2021) 6:e006351. doi: 10.1136/bmjgh-2021-006351
3. Lung T, Jan S, Tan EJ, Killeard A, Hayes A. Impact of overweight, obesity and severe obesity on life expectancy of Australian adults. Int J Obes (Lond). (2019) 43:782–9. doi: 10.1038/s41366-018-0210-2
4. Hruby A, Manson JE, Qi L, Malik VS, Rimm EB, Sun Q, et al. Determinants and consequences of obesity. Am J Public Health. (2016) 106:1656–62.
5. Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected – obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. (2021) 17:135–49. doi: 10.1038/s41574-020-00462-1
6. Stefan N. Metabolic disorders, COVID-19 and vaccine-breakthrough infections. Nat Rev Endocrinol. (2022) 18:75–6. doi: 10.1038/s41574-021-00608-9
7. Tsatsoulis A, Paschosou SA. Metabolically healthy obesity: criteria, epidemiology, controversies, and consequences. Curr Obes Rep. (2020) 9:190–20. doi: 10.1007/s13679-020-00375-0
8. Lin H, Zhang L, Zheng R, Zheng Y. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: a PRISMA-compliant article. Medicine. (2017) 96:e8838. doi: 10.1097/MD.0000000000008838
9. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, Doiron D, Fischer K, Foco L, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. (2014) 14:9. doi: 10.1186/1472-6823-14-9
10. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab. (2012) 97:2488–9. doi: 10.1210/jc.2011-3475
11. Eckel N, Meidtner K, Kalle-Uhlmann T, Stefan N, Schulze MB. Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis. Eur J Prev Cardiol. (2016) 23:956–66. doi: 10.1177/2047487315623884
12. Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes Rev. (2014) 15:504–15. doi: 10.1111/obr.12157
13. Blüher M. Metabolically healthy obesity. Endor Rev. (2020) 41:405–20.
14. Stefan N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol. (2020) 8:616–27. doi: 10.1016/s2213-8587(20)30110-8
15. Goossens GH. The metabolic phenotype in obesity: fat mass, body fat distribution, and adipose tissue function. Obes Facts. (2017) 10:207–15. doi: 10.1159/000471488
16. Eckel N, Li Y, Kuxhaus O, Stefan N, Hu FB, Schulze MB. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the nurses’ health study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. (2018) 6:714–24. doi: 10.1016/s2213-8587(18)30137-2
17. Stefan N, Häring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol. (2018) 6:249–58. doi: 10.1016/s2213-8587(17)30292-9
18. Castro-Barquero S, Ruiz-León AM, Sierra-Pérez M, Estruch R, Casas R. Dietary strategies for metabolic syndrome: a comprehensive review. Nutrients. (2020) 12:2983. doi: 10.3390/nu12102983
19. Estruch R, Martinez-González MA, Corella D, Salas-Salvadó J, Fité M, Chiva-Blanch G, et al. Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: a prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial. Lancet Diabetes Endocrinol. (2019) 7:e6–17. doi: 10.1016/s2213-8587(19)30074-9
20. Romaguera D, Norat T, Vergnaud AC, Mouw T, May AM, Agudo A, et al. Mediterranean dietary patterns and prospective weight change in participants of the EPIC-PANACEA project. Am J Clin Nutr. (2010) 92:912–21. doi: 10.3945/ajcn.2010.29482
21. Agnoli C, Sieri S, Ricceri F, Giraudo MT, Masala G, Assedi M, et al. Adherence to a Mediterranean diet and long-term changes in weight and waist circumference in the EPIC-Italy cohort. Nutr Diabetes. (2018) 8:22. doi: 10.1038/s41387-018-0023-3
22. Esposito K, Kastorini CM, Panagiotakos DB, Giugliano D. Mediterranean diet and weight loss: meta-analysis of randomized controlled trials. Metabol Syndr Relat Disord. (2011) 9:1–12. doi: 10.1089/met.2010.0031
23. Beunza JJ, Toledo E, Hu FB, Bes-Rastrollo M, Serrano-Martínez M, Sánchez-Villegas A, et al. Adherence to the Mediterranean diet, long-term weight change, and incident overweight or obesity: the seguimiento universidad de Navarra (SUN) cohort. Am J Clin Nutr. (2010) 92:1484–93. doi: 10.3945/ajcn.2010.29764
24. Eguraz S, Toledo E, Hernández-Hernández A, Cervantes S, Martínez-González MA. Better adherence to the Mediterranean diet could mitigate the adverse consequences of obesity on cardiovascular disease: the sun prospective cohort. Nutrients. (2015) 7:1545–62. doi: 10.3390/nu7115457
25. Esposito K, Kastorini CM, Panagiotakos DB, Giugliano D. Mediterranean diet and metabolic syndrome: an updated systematic review. Rev Endocrin Metab Disord. (2013) 14:255–63. doi: 10.1007/s11154-013-9253-9
26. Sureda A, Bibiloni MDM, Julibert A, Bouzas C, Argelich E, Llompart I, et al. Adherence to the Mediterranean diet and inflammatory markers. Nutrients. (2018) 10:62. doi: 10.3390/nu10010062
27. Bertoli S, Leone A, Vagniti L, Bedogni G, Martinez-González MA, Bes-Rastrollo M, et al. Adherence to the Mediterranean diet is inversely associated with visceral abdominal tissue in caucasian subjects. Clin Nutr. (2015) 34:1266–72. doi: 10.1016/j.clnu.2015.10.003
28. Hennein R, Liu C, McKeown NM, Hoffmann U, Long MT, Levy D, et al. Increased diet quality is associated with long-term reduction of abdominal and pericardial fat. Obesity (Silver Spring). (2019) 27:670–7. doi: 10.1002/oby.22427
29. Armellini F, Zamboni M, Rigo L, Todesco T, Bergamo-Andrèis IA, Proacci C, et al. The contribution of sonography to the measurement of intra-abdominal fat. J Clin Ultrasound. (1990) 18:563–7. doi: 10.1002/jcu.1870180707
30. Bertoli S, Leone A, Vagniti L, Spadafranca A, Bedogni G, Vanzulli A, et al. Metabolic correlates of subcutaneous and visceral abdominal fat measured by ultrasonography: a comparison with waist circumference. Nutr J. (2016) 15:2.
31. Chobanian AV, Bakрис GL, Black HR, Cushman WC, Green LA, Izzo JLL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressurethe JNC 7 report. JAMA. (2003) 289:2560–71. doi: 10.1001/jama.289.19.2560
32. Lohman TG, Roche AF, Martorell R. Anthropometric Standardization Reference Manual. Champaign, IL: Human Kinetics Books (1988).
33. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. Geneva: World Health Organization (2000).

34. Lavie CJ, Laddu D, Arena R, Ortega FB, Alpert MA, Kushner RF. Healthy weight and obesity prevention: JACC health promotion series. J Am Coll Cardiol. (2017) 72:1566–71.

35. Schröder H, Fitó M, Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. J Nutr. (2011) 141:1140–5. doi: 10.3945/jn.110.135566

36. Amics RD, Leone A, Foppiani A, Osio D, Lewandowski L, Giustizieri V, et al. Mediterranean diet and cognitive status in free-living elderly: a cross-sectional study in Northern Italy. J Am Coll Nutr. (2018) 37:494—500. doi: 10.1080/07315724.2018.1442263

37. Bertotti S, Spadafranca A, Bes-Rastrollo M, Martínez-González MA, Ponisii V, Beggio V, et al. Adherence to the Mediterranean diet is inversely related to binge eating disorder in patients seeking a weight loss program. Clin Nutr. (2015) 34:107–14. doi: 10.1016/j.clnu.2014.02.001

38. León-Muñoz LM, Guallar-Castillón P, Graciani A, López-García E, Messa AE, Aguilera MT, et al. Adherence to the Mediterranean diet pattern has declined in Spanish adults. J Nutr. (2012) 142:1843–50. doi: 10.3945/jn.112.164616

39. Hosmer DW Jr., Lemeshow S, Sturdivant RX. Applied Logistic Regression. 3rd ed. Hoboken, NJ: John Wiley & Sons (2013).

40. Phillips CM, Dillon C, Ortega FB, Alpert MA, Kushner RF, De Amicis R, et al. Defining metabolically healthy obesity: role of dietary and lifestyle factors. PLoS One. (2013) 8:e76188. doi: 10.1371/journal.pone.0076188

41. Hankinson AL, Daviglus ML, Van Horn L, Chan Q, Brown I, Holmes E, et al. Diet composition and activity level of at risk and metabolically healthy obese American adults. Obesity (Silver Spring). (2013) 21:637–43. doi: 10.1002/oby.20257

42. Kimkoti RW, Judd SE, Shikamy JM, Newby PK. Metabolically healthy obesity is not associated with food intake in white or black men. J Nutr. (2015) 145:2551–61. doi: 10.3945/jn.115.221283

43. Schulze MB, Martínez-González MA, Fung TT, Lichtenstein AH, Forouhi NG, Food based dietary patterns and chronic disease prevention. BMJ. (2016) 361:2396. doi: 10.1136/bmj.b3966

44. Tapsell LC, Neale EP, Satija A, Hu FB. Foods, nutrients, and dietary patterns: interconnections and implications for dietary guidelines. Adv Nutr. (2016) 7:445–54. doi: 10.3945/an.115.011718

45. Leone A, Fernández-Montero A, de la Fuente-Arrillaga C, Martínez-González M, Bertoli S, Battezzati A. Adherence to the Mediterranean dietary pattern and incidence of nephrolithiasis in the seguimiento universidad de navarra follow-up (SUN) cohort. (2017) 70:778–86. doi: 10.1053/j.ajkd.2017.06.027

46. Leone A, Martínez-González MA, Sánchez-Bayona R, de la Fuente-Arrillaga C, Martínez-González M, Corella D, Graciani A, López-García E, Mesas AE, Salas-Salvadó J, et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. J Nutr. (2011) 141:1140–5. doi: 10.3945/jn.110.135566

47. Leone A, Battezzati A, De Amicis R, De Carlo G, Bertoli S, Trends of adherence to the Mediterranean dietary pattern in Northern Italy from 2010 to 2016. Nutrients. (2017) 9:734. doi: 10.3390/nu9070734

48. Deibert P, König D, Vitolins MZ, Landmann U, Frey I, Zahradnik HP, et al. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut. (2021) 70:2085. doi: 10.1136/gutjnl-2020-123106

49. Gepner Y, Shelef I, Komy O, Cohen N, Schwarzhufs D, Bril N, et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol. (2019) 71:379–88. doi: 10.1016/j.jhep.2019.04.013

50. Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. (2019) 7:313–24. doi: 10.1016/S2213-8587(18)30154-2

51. Gantengan BS, Kataoka BS, Gantengan BN. Mediterranean diet as an antioxidant: the impact on metabolic health and overall wellbeing. Nutrients. (2021) 13:1951. doi: 10.3390/nu13061951

52. Billingsley HE, Carbone S. The antioxidant potential of the Mediterranean diet in patients at high cardiovascular risk: an in-depth review of the PREMED. Nutr Diabetes. (2018) 8:13. doi: 10.1038/s41387-018-0025-1

53. Barbarese K, Koch M, Schulze MB, Nothlings U. Dietary pattern analysis and biomarkers of low-grade inflammation: a systematic literature review. Nutr Rev. (2013) 71:511–27. doi: 10.1111/nure.12035

54. Ruiz-Núñez B, Bijck-Brouwer DA, Muskiet FA. The relation of saturated fatty acids with low-grade inflammation and cardiovascular disease. J Nutr Biochem. (2016) 36:1–20. doi: 10.1016/j.jnutbio.2015.12.007

55. Longo M, Zatteralle F, Naderi J, Parrillo L, Formisano P, Raciti GA, et al. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int J Mol Sci. (2019) 20:2358. doi: 10.3390/ijms20092358

56. Stolk RP, Wink O, Zelissen PM, Meijer R, van Gils AP, Grobbee DE. Validity and reproducibility of ultrasonography for the measurement of intra-abdominal adipose tissue. Int J Obes Relat Metab Disord. (2001) 25:1346–51.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Leone, De Amicis, Battezzati and Bertoli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.